AQUABOUNTY TECHNOLOGIES INCAQBEarnings & Financial Report
AquaBounty Technologies is a biotechnology and aquaculture company based in Maynard, Massachusetts, United States. The company is notable for its research and development of genetically modified fish. It aims to create products that aim to increase the productivity of aquaculture. As of 2020, sale of the company's AquAdvantage salmon has been approved in Canada and the United States. The company sold all of its operating farms and ceased fish production in 2024.
AQB Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-1.5M
Net Profit
$-1.4M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.36
AQUABOUNTY TECHNOLOGIES INC Q3 2025 Financial Summary
AQUABOUNTY TECHNOLOGIES INC reported revenue of $0 for Q3 2025, with a net profit of $-1.4M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-1.4M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
AQUABOUNTY TECHNOLOGIES INC Annual Revenue by Year
AQUABOUNTY TECHNOLOGIES INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2024 | $0 |
| 2023 | $2.5M |
| 2022 | $3.1M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $553250 | $477268 | $180182 | $47812 | $-705262 | $0 | $0 | $0 |
| YoY Growth | 22.7% | 20.0% | -77.1% | -93.5% | -227.5% | N/A | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $187.6M | $176.2M | $127.4M | $117.8M | $34.1M | $29.4M | $26.7M | $24.2M |
| Liabilities | $22.5M | $22.3M | $24.1M | $17.7M | $18.2M | $12.5M | $13.0M | $11.9M |
| Equity | $165.0M | $153.8M | $103.3M | $100.1M | $15.8M | $17.0M | $13.6M | $12.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.8M | $-4.4M | $-4.3M | $-4.0M | $-1.2M | $-2.4M | $-1.5M | $-1.7M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M